IL-37 Was Involved in Progress of Acute Myeloid Leukemia Through Regulating IL-6 Expression

References

• Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136–1152. doi:10.1056/NEJMra140618426376137
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-64354427069254
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25(11):1315–1321. doi:10.1038/nbt135017952057
   PubMed Web of Science ®Google Scholar
• Ho TC, LaMere M, Stevens BM, et al. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 2016;128(13):1671–1678. doi:10.1182/blood-2016-02-69531227421961
   PubMed Web of Science ®Google Scholar
• Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, Sims JE. Four new members expand the interleukin-1 superfamily. J Biol Chem. 2000;275(2):1169–1175. doi:10.1074/jbc.275.2.116910625660
   PubMed Web of Science ®Google Scholar
• Kumar S, McDonnell PC, Lehr R, et al. Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem. 2000;275(14):10308–10314. doi:10.1074/jbc.275.14.1030810744718
   PubMed Web of Science ®Google Scholar
• Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11(11):1014–1022. doi:10.1038/ni.194420935647
   PubMed Web of Science ®Google Scholar
• Tete S, Tripodi D, Rosati M, et al. IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation. Int J Immunopathol Pharmacol. 2012;25(1):31–38. doi:10.1177/03946320120250010522507315
   PubMed Web of Science ®Google Scholar
• Taylor SL, Renshaw BR, Garka KE, Smith DE, Sims JE. Genomic organization of the interleukin-1 locus. Genomics. 2002;79(5):726–733. doi:10.1006/geno.2002.675211991723
   PubMed Web of Science ®Google Scholar
• Boraschi D, Lucchesi D, Hainzl S, et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw. 2011;22(3):127–147. doi:10.1684/ecn.2011.028822047735
   PubMed Web of Science ®Google Scholar
• Chen H-M, Fujita M. IL-37: a new player in immune tolerance. Cytokine. 2015;72(1):113–114. doi:10.1016/j.cyto.2014.11.02525592113
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Nold-Petry C, Nold M, et al. Suppression of innate inflammation and immunity by interleukin-37. Eur J Immunol. 2016;46(5):1067–1081. doi:10.1002/eji.20154582827060871
   PubMed Web of Science ®Google Scholar
• McNamee EN, Masterson JC, Jedlicka P, et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A. 2011;108(40):16711–16716. doi:10.1073/pnas.111198210821873195
   PubMed Web of Science ®Google Scholar
• Ballak DB, van Diepen JA, Moschen AR, et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 2014;5:4711. doi:10.1038/ncomms571125182023
   PubMed Web of Science ®Google Scholar
• Ye L, Jiang B, Deng J, et al. IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-triggering cytokine production and limiting Th17 cell proliferation. J Immunol. 2015;194(11):5110–5119. doi:10.4049/jimmunol.140181025917106
   PubMed Web of Science ®Google Scholar
• Ye L, Ji L, Wen Z, et al. IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity. J Transl Med. 2014;12:69. doi:10.1186/1479-5876-12-6924629023
   PubMed Web of Science ®Google Scholar
• Bulau AM, Fink M, Maucksch C, et al. In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis. Sci World J. 2011;11:2480–2490. doi:10.1100/2011/968479
   Web of Science ®Google Scholar
• Teng X, Hu Z, Wei X, et al. IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production. J Immunol. 2014;192(4):1815–1823. doi:10.4049/jimmunol.130004724453242
   PubMed Web of Science ®Google Scholar
• Li Y, Zhao M, Guo C, et al. Intracellular mature IL-37 suppresses tumor metastasis via inhibiting Rac1 activation. Oncogene. 2018;37(8):1095–1106. doi:10.1038/onc.2017.40529106392
   PubMed Web of Science ®Google Scholar
• Wang S, An W, Yao Y, et al. Interleukin 37 expression inhibits STAT3 to suppress the proliferation and invasion of human cervical cancer cells. J Cancer. 2015;6(10):962–969. doi:10.7150/jca.1226626316892
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Pan QZ, Pan K, et al. Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells. Sci Rep. 2014;4:5177. doi:10.1038/srep0517724898887
   PubMed Web of Science ®Google Scholar
• Li ZC, Sun MD, Zheng YQ, Fu HJ. The low expression of IL-37 involved in multiple myeloma - associated angiogenesis. Med Sci Monit. 2016;22:4164–4168. doi:10.12659/MSM.89745127807338
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Bjorkholm M, Hultcrantz M, Derolf AR, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011;29(21):2897–2903. doi:10.1200/JCO.2011.34.854021690473
   PubMed Web of Science ®Google Scholar
• Ramadan SM, Fouad TM, Summa V, Hasan S, Lo-Coco F. Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica. 2012;97(6):805–817. doi:10.3324/haematol.2011.05628322180424
   PubMed Web of Science ®Google Scholar
• Binder S, Luciano M, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev. 2018;43:8–15. doi:10.1016/j.cytogfr.2018.08.00430181021
   PubMed Web of Science ®Google Scholar
• Brazvan B, Farahzadi R, Mohammadi S, et al. Key immune cell cytokines affects the telomere activity of cord blood cells in vitro. Adv Pharm Bull. 2016;6:153–161. doi:10.15171/apb.2016.02227478776
   PubMedGoogle Scholar
• Verma G, Raigond B, Pathania S, Kochhar T, Naga K. Development and comparison of reverse transcription-loop-mediated isothermal amplification assay (RT-LAMP), RT-PCR and real time PCR for detection of Potato spindle tuber viroid in potato. Eur J Plant Pathol. 2020;158:951–964. doi:10.1007/s10658-020-02129-z
   Web of Science ®Google Scholar
• Huh H, Park J, Kim J, et al. Performance of the Real-Q EBV quantification kit for epstein-barr virus DNA quantification in whole blood. Ann Lab Med. 2017;37:147–150. doi:10.3343/alm.2017.37.2.14728029001
   PubMed Web of Science ®Google Scholar
• Sun X, Ge X, Xu Z, Chen D. Identification of circular RNA–microRNA–messenger RNA regulatory network in hepatocellular carcinoma by integrated analysis. J Gastroenterol Hepatol. 2019;35:157–164. doi:10.1111/jgh.1476231222831
   PubMed Web of Science ®Google Scholar
• Fathi E, Valipour B, Sanaat Z, Nozad Charoudeh H, Farahzadi R. Interleukin-6, −8, and TGF-β secreted from mesenchymal stem cells show functional role in reduction of telomerase activity of leukemia cell via Wnt5a/β-Catenin and P53 pathways. Adv Pharm Bull. 2020;10:307–314. doi:10.34172/apb.2020.03732373501
   PubMed Web of Science ®Google Scholar
• Farahzadi R, Fathi E, Vietor I. Mesenchymal stem cells could be considered as a candidate for further studies in cell-based therapy of alzheimer’s disease via targeting the signaling pathways. ACS Chem Neurosci. 2020;11:1424–1435. doi:10.1021/acschemneuro.0c0005232310632
   PubMed Web of Science ®Google Scholar
• Abulkhir A, Samarani S, Amre D, et al. A protective role of IL-37 in cancer: a new hope for cancer patients. J Leukoc Biol. 2017;101(2):395–406. doi:10.1189/jlb.5RU0816-341R27881603
   PubMed Web of Science ®Google Scholar
• Quirk S, Agrawal DK. Immunobiology of IL-37: mechanism of action and clinical perspectives. Expert Rev Clin Immunol. 2014;10(12):1703–1709. doi:10.1586/1744666X.2014.97101425327443
   PubMed Web of Science ®Google Scholar
• Bufler P, Gamboni-Robertson F, Azam T, Kim SH, Dinarello CA. Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem J. 2004;381(Pt 2):503–510. doi:10.1042/BJ2004021715046617
   PubMed Web of Science ®Google Scholar
• Carey A, Edwards D, Eide CA, et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017;18(13):3204–3218. doi:10.1016/j.celrep.2017.03.01828355571
   PubMed Web of Science ®Google Scholar
• Jia H, Liu J, Han B. Reviews of interleukin-37: functions, receptors, and roles in diseases. BioMed Res Int. 2018;2018:1–14.
   Web of Science ®Google Scholar
• Zhao M, Li Y, Guo C, et al. IL-37 isoform D downregulates pro-inflammatory cytokines expression in a Smad3-dependent manner. Cell Death Dis. 2018;9(6):582. doi:10.1038/s41419-018-0664-029789615
   PubMed Web of Science ®Google Scholar
• Pourrajab F, Zare-Khormizi MR, Hashemi AS, Hekmatimoghaddam S. Genetic characterization and risk stratification of acute myeloid leukemia. Cancer Manag Res. 2020;12:2231. doi:10.2147/CMAR.S24247932273762
   PubMed Web of Science ®Google Scholar
• Dohner K, Döhner H. Molecular characterization of acute myeloid leukemia. Haematologica. 2008;93(7):976–982. doi:10.3324/haematol.1334518591623
   PubMed Web of Science ®Google Scholar
• Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol. 2009;37(6):649–658. doi:10.1016/j.exphem.2009.04.00219463767
   PubMed Web of Science ®Google Scholar
• Martelli MP, Sportoletti P, Tiacci E, Martelli MF, Falini B. Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Rev. 2013;27(1):13–22. doi:10.1016/j.blre.2012.11.00123261068
   PubMed Web of Science ®Google Scholar
• Van Loo P, Doornbos R, Dolstra H, Shamsili S, Bakker L. Preclinical evaluation of MCLA117, a CLEC12AxCD3 bispecific antibody efficiently targeting a novel leukemic stem cell associated antigen in AML. Blood. 2015;126:325. doi:10.1182/blood.V126.23.325.325
   Web of Science ®Google Scholar
• Hou D, Wang B, You R, et al. Stromal cells promote chemoresistance of acute myeloid leukemia cells via activation of the IL-6/STAT3/OXPHOS axis. Ann Transl Med. 2020;8:1346. doi:10.21037/atm-20-319133313091
   PubMed Web of Science ®Google Scholar
• Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A. 1987;84(24):9035–9039. doi:10.1073/pnas.84.24.90353501121
   PubMed Web of Science ®Google Scholar
• Oster W, Cicco NA, Klein H, et al. Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest. 1989;84(2):451–457. doi:10.1172/JCI1141862788173
   PubMed Web of Science ®Google Scholar
• Monlish DA, Bhatt ST, Schuettpelz LG. The role of toll-like receptors in hematopoietic malignancies. Front Immunol. 2016;7:390. doi:10.3389/fimmu.2016.0039027733853
   PubMed Web of Science ®Google Scholar
• Rybka J, Butrym A, Wrobel T, et al. The expression of Toll-like receptors in patients with acute myeloid leukemia treated with induction chemotherapy. Leuk Res. 2015;39(3):318–322. doi:10.1016/j.leukres.2015.01.00225624047
   PubMed Web of Science ®Google Scholar
• Wang X, Smith C, Yin H. Targeting Toll-like receptors with small molecule agents. Chem Soc Rev. 2013;42(12):4859–4866. doi:10.1039/c3cs60039d23503527
   PubMed Web of Science ®Google Scholar
• De Nardo D. Toll-like receptors: activation, signalling and transcriptional modulation. Cytokine. 2015;74(2):181–189. doi:10.1016/j.cyto.2015.02.02525846205
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–384. doi:10.1038/ni.186320404851
   PubMed Web of Science ®Google Scholar